Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis

Fertil Steril. 2010 Nov;94(6):2365-8. doi: 10.1016/j.fertnstert.2010.03.076. Epub 2010 May 13.

Abstract

In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). Steady-state plasma concentrations of E2 and estrone were one-third lower after vaginal versus oral administration of conjugated estrogens.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravaginal
  • Administration, Oral
  • Aged
  • Atrophy / blood
  • Atrophy / drug therapy
  • Atrophy / metabolism
  • Cross-Over Studies
  • Drug Administration Schedule
  • Estradiol / blood*
  • Estrogens, Conjugated (USP) / administration & dosage*
  • Estrogens, Conjugated (USP) / blood
  • Estrogens, Conjugated (USP) / pharmacokinetics
  • Estrone / blood
  • Female
  • Humans
  • Middle Aged
  • Osmolar Concentration
  • Vagina / drug effects
  • Vagina / pathology*
  • Vaginal Creams, Foams, and Jellies
  • Vaginitis / blood
  • Vaginitis / drug therapy*
  • Vaginitis / metabolism

Substances

  • Estrogens, Conjugated (USP)
  • Vaginal Creams, Foams, and Jellies
  • Estrone
  • Estradiol